Literature DB >> 7306699

The presence and release of alpha 2-antiplasmin from human platelets.

E F Plow, D Collen.   

Abstract

An antigen immunochemically indistinguishable from plasma alpha 2-antiplasmin, the primary plasmin inhibitor, was detected in human platelets. By radioimmunoassay, 33-114 ng alpha 2-antiplasmin antigen was quantitated in the detergent-soluble extract of 10(9) washed human platelets from 10 normal donors with a mean level of 62 +/- 24 ng/10(9) platelets. Plasma alpha 2-antiplasmin, either in the platelet suspending medium or on the surface of the platelets, could account for less than 8% of the antigen present in the platelet extracts. When stimulated with thrombin, the platelets released alpha 2-antiplasmin antigen without cell lysis, and greater than 85% of the alpha 2-antiplasmin antigen was released at a high thrombin dose. At a lower dose of thrombin, alpha 2-antiplasmin and platelet factor 4 were partially released without concomitant secretion of serotonin. No alpha 2-antiplasmin antigen was detected in extracts or red blood cells, polymorphonuclear leukocytes, and adherent and nonadherent mononuclear cells. Thus, the platelet is the only peripheral blood cell containing significant amounts of alpha 2-antiplasmin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7306699

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 2.  Glomerular fibrin deposition and removal.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

3.  Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Authors:  Kanagasabai Vadivel; Sathya-Moorthy Ponnuraj; Yogesh Kumar; Anne K Zaiss; Matthew W Bunce; Rodney M Camire; Ling Wu; Denis Evseenko; Harvey R Herschman; Madhu S Bajaj; S Paul Bajaj
Journal:  J Biol Chem       Date:  2014-09-28       Impact factor: 5.157

4.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

5.  Plasminogen interacts with human platelets through two distinct mechanisms.

Authors:  L A Miles; M H Ginsberg; J G White; E F Plow
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Detection and partial characterization of an inhibitor of plasminogen activator in human platelets.

Authors:  L A Erickson; M H Ginsberg; D J Loskutoff
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

Review 7.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

8.  Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction.

Authors:  V L Serebruany; D Atar; S R Murugesan; S Jerome; H Semaan; P A Gurbel
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

9.  Lack of alpha 2-antiplasmin enhances ADP induced platelet micro-aggregation through the presence of excess active plasmin in mice.

Authors:  Mariko Takei; Hiroyuki Matsuno; Kiyotaka Okada; Shigeru Ueshima; Osamu Matsuo; Osamu Kozawa
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 10.  Biomaterials and Advanced Technologies for Hemostatic Management of Bleeding.

Authors:  DaShawn A Hickman; Christa L Pawlowski; Ujjal D S Sekhon; Joyann Marks; Anirban Sen Gupta
Journal:  Adv Mater       Date:  2017-11-22       Impact factor: 30.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.